These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 10370777)

  • 1. Drug combinations: dangerous liaisons or great expectations?
    Ratain MJ
    Ann Oncol; 1999 Apr; 10(4):375-6. PubMed ID: 10370777
    [No Abstract]   [Full Text] [Related]  

  • 2. Palbociclib: first global approval.
    Dhillon S
    Drugs; 2015 Apr; 75(5):543-51. PubMed ID: 25792301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Counterpoint: Standard vs Investigational Agents as Upfront Treatment for High-Risk AML.
    Brunner AM; Stock W
    Oncology (Williston Park); 2017 Mar; 31(3):190, 192. PubMed ID: 28299756
    [No Abstract]   [Full Text] [Related]  

  • 4. Point: Standard vs Investigational Agents as Upfront Treatment for High-Risk AML.
    Schiffer CA
    Oncology (Williston Park); 2017 Mar; 31(3):190-1. PubMed ID: 28299755
    [No Abstract]   [Full Text] [Related]  

  • 5. Assessing Novel Therapies Based on Late-Stage Efficacy: A Dangerous Concept?
    Lønning PE
    Trends Cancer; 2021 Mar; 7(3):181-185. PubMed ID: 33358430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Other options in the treatment of advanced breast cancer.
    Cobleigh MA
    Semin Oncol; 2011 Jun; 38 Suppl 2():S11-6. PubMed ID: 21600380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trials. Experimental cancer therapies move to the front line.
    Couzin-Frankel J
    Science; 2012 Jan; 335(6066):282-3. PubMed ID: 22267789
    [No Abstract]   [Full Text] [Related]  

  • 8. Cancer drugs. Weighing the risks and benefits.
    Bren L
    FDA Consum; 2007; 41(1):10-9. PubMed ID: 17342832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of lonidamine in patients with metastatic breast cancer. An Eastern Cooperative Oncology Group study.
    Robins HI; Neuberg DS; Benson AB; Pandya KJ; Tormey DC
    Invest New Drugs; 1990 Nov; 8(4):397-9. PubMed ID: 2084074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigational drug combined with chemotherapy improves response in patients with BRCA-mutant breast cancer.
    Printz C
    Cancer; 2017 Mar; 123(5):722-723. PubMed ID: 28221688
    [No Abstract]   [Full Text] [Related]  

  • 11. Waldenström macroglobulinemia: is newer really better?
    Gertz MA
    Leuk Lymphoma; 2010 Dec; 51(12):2152-3. PubMed ID: 21067441
    [No Abstract]   [Full Text] [Related]  

  • 12. SOP 02: Evaluation and selection of a clinical trial proposal for CESAR.
    Onkologie; 2003 Oct; 26 Suppl 6():5-10. PubMed ID: 23570178
    [No Abstract]   [Full Text] [Related]  

  • 13. [Innovative drugs for the good of the patients].
    Dietrich W
    Krankenpfl J; 2005; 43(4-6):136. PubMed ID: 16171078
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of rational drug combinations with investigational targeted agents.
    Clark A; Ellis M; Erlichman C; Lutzker S; Zwiebel J
    Oncologist; 2010; 15(5):496-9. PubMed ID: 20489187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Castration refractory prostate cancer: cinderella finally comes to the ball.
    Chowdhury S; Harper P; Powles T
    Onkologie; 2010; 33(12):655-6. PubMed ID: 21124035
    [No Abstract]   [Full Text] [Related]  

  • 16. SOP 08: Reporting of adverse events.
    Onkologie; 2003 Oct; 26 Suppl 6():41-2. PubMed ID: 23570185
    [No Abstract]   [Full Text] [Related]  

  • 17. Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity.
    Hesketh PJ; Gralla RJ; du Bois A; Tonato M
    Support Care Cancer; 1998 May; 6(3):221-7. PubMed ID: 9629873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel agents and future directions for refractory breast cancer.
    Burstein HJ
    Semin Oncol; 2011 Jun; 38 Suppl 2():S17-24. PubMed ID: 21600381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adaptive trials receive boost.
    Jones D
    Nat Rev Drug Discov; 2010 May; 9(5):345-8. PubMed ID: 20414200
    [No Abstract]   [Full Text] [Related]  

  • 20. Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review.
    Holmes FA
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):46-56. PubMed ID: 8893900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.